Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
The Efficacy and Safety of Traditional Chinese Medicine Qufenghuoxue Formula on Treating Peripheral Neuropathy Induced by Paclitaxel in Advanced Lung Cancer: A Randomized Clinical Trial.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo assess the benefits of the traditional Chinese medicine (TCM) Qufenghuoxue formula, on the treatment of chemotherapy-induced peripheral neuropathy (CIPN) in patients with lung cancer receiving paclitaxel (PTX).
methodsPatients with CIPN grading 2-3 were randomly assigned to three groups of TCM, vitamin B1, or warm water. The intervention duration consisted of four cycles, 3 weeks each, coinciding with the follow-up period. Primary efficacy endpoint was the proportion of patients achieving CIPN relief, defined by reduction in CIPN severity grade, while secondary endpoint evaluated completion of the recommended PTX dosing.
resultsTCM significantly reduced grade 2-3 CIPN incidence and increased symptom relief (48.6% vs 12.0% vs 7.5%; P < 0.001) with a shorter median time to recovery compared with vitamin B1 and warm water, respectively. Additionally, it improved scores of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity subscale (11.5 vs 20.4 vs 22.4), neuropathy pain scale (16.8 vs 27.7 vs 29.2) and quality of life (42.6 vs 36.0 vs 33.6; all P < 0.001) and also showed greater potential of completing the recommended dose level of PTX (83.8% vs 74.6% vs 59.7%; P = 0.0034) compared with vitamin B1 and warm water. With warm water as reference, the hazard ratio of PTX dose reductions/cessation due to CIPN was 0.34 (95% confidence interval [CI]: 0.168-0.67, P = 0.002) for TCM and 0.56 (95% CI: 0.314-1.008; P = 0.053) for vitamin B1.
conclusionQufenghuoxue formula may be a promising strategy for the treatment of CIPN in patients receiving PTX. Trial Registration Chinese Clinical Trial Registry; No.: ChiCTR2300069949. Registered 30 March 30, 2023, URL: www.chictr.org/cn/ .
Indexed as
Identifiers
41428261What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.